<DOC>
	<DOCNO>NCT01629966</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability vilazodone relative placebo treatment generalize anxiety disorder ( GAD )</brief_summary>
	<brief_title>Safety , Efficacy Tolerability Vilazodone Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Male female , 18 70 year age Currently meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion Generalized Anxiety Disorder ( GAD ) Minimum score 20 Hamilton Rating Scale Anxiety ( HAMA ) Women pregnant , woman breastfeed study woman childbearing potential practicing reliable method birth control Patients history meeting DSMIVTR criterion Any manic hypomanic mixed episode , include bipolar disorder substanceinduced manic , hypomanic mixed episode Any depressive episode psychotic catatonic feature Panic disorder without agoraphobia Obsessivecompulsive disorder Schizophrenia , schizoaffective , psychotic disorder Bulimia anorexia nervosa Presence borderline personality disorder antisocial personality disorder Mental retardation , dementia , amnesia , significant cognitive disorder Patients consider suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>GAD</keyword>
</DOC>